^
    Back
    Association details:
    Biomarker:RPL10 R98S
    Cancer:T Acute Lymphoblastic Leukemia
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Leukemia
    Title:

    The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL

    Published date:
    06/21/2018
    Excerpt:
    RPL10 R98S selective sensitivity to the clinically available Bcl-2 inhibitor Venetoclax (ABT-199) was supported by suppression of splenomegaly and the absence of human leukemia cells in the blood of T-ALL xenografted mice.
    DOI:
    10.1038/s41375-018-0176-z